Background: The recent approval of more potent and better-tolerated therapies for HCV infection, including in those with HIV-1 co-infection, heralds the beginning of a new era in HCV therapeutics. Interferon-free therapy is the new standard of care for patients with genotype 2 or 3 HCV infection; while highly efficacious IFN-containing triple therapies with a shortened duration are an option for those with genotype 1 HCV infection. As HCV therapy becomes less complex and as expanded screening efforts are implemented, more providers will be needed to accommodate the increased number of patients wanting or requiring HCV therapy. While the recent advances have brought significant improvements in HCV therapy for genotype 1 infection, more advances are expected over the next 1-2 years, in particular the arrival of interferon-free therapy. Thus many clinicians are faced with the complex issue of deciding whether to initiate therapy now or defer with the promise of better therapies in the near future. An understanding of the clinical trial data summarizing new and future treatment regimens as well a review of the complexity of management in the HIV-1 infected patient population including but not limited to drug-drug interactions will be discussed. Conclusions: This interactive case-based session is geared toward clinicians who are new to HCV care and will cover key aspects related to: 1) decision making on HCV treatment initiation versus deferral, 2) use of interferon-free therapy for HCV genotype 2 and 3 infection, 3) recognizing advanced and early decompensated liver disease, and 4) managing HCV therapy and drug interaction in a co-infected patient with genotype 1 infection.